Skip to main content
. 2017 May 12;7:1853. doi: 10.1038/s41598-017-01913-y

Figure 1.

Figure 1

Expression of ALOX5 is significantly down-regulated in MLL-rearranged AML. (a) Comparison of ALOX5 expression between t(11q23)/MLL-rearranged AML and AML cases with inv(16), t(8;21) or t(15;17), or normal controls (NC) in our in-house AML dataset2729. (b) Comparison of ALOX5 expression between t(11q23) AML and other subtypes of AML cases in GSE1446830. The expression values were log2-transformed and mean centered. The P values were detected by t-test. (c,d) Downregulation of Alox5 in MLL-AF9-AML mouse BM mononuclear cells, as compared with normal controls. Levels of Alox5 were detected through qPCR (c) and Western blotting (d). (eg) EZH2 and SIN3A bind the promoter of ALOX5. Enrichment of MLL-N terminal (for both wild-type MLL and MLL fusions), MLL-C terminal (for wild-type MLL), EZH2, SIN3A, H3K27me3 or IgG at the ALOX5 promoter region was shown. Relative to transcription start site of ALOX5, locations of the three PCR amplicon sites are: ALOX5-A (e): −522~−234 bp; ALOX5-B (f): −259~−79 bp; ALOX5-C (g): +149~+596 bp32. *P < 0.05; **P < 0.01, two-tailed t-test.